Merck Gains Despite 25% Drop in Trading Volume Keytruda Growth Drives Market Cap Rank

, 2025, , . The stock’s performance reflects ongoing dynamics in its oncology portfolio and strategic initiatives. Keytruda, Merck’s flagship drug, continues to drive revenue despite patent expiration risks in 2028. , supported by expanded indications in early-stage lung cancer and partnerships, including a collaboration with Moderna to develop an mRNA-based cancer vaccine. The subcutaneous formulation of Keytruda, under FDA review, could extend its patent life.

Merck’s pipeline expansion and M&A activity highlight its focus on diversification. , a COPD treatment, to strengthen its cardio-pulmonary portfolio. New launches, such as the pneumococcal vaccine Capvaxive and pulmonary hypertension drug Winrevair, are showing strong initial traction. However, Gardasil, Merck’s second-largest product, . Reduced shipments in China, where inventory levels remain elevated, are expected to persist through 2025.

, challenges remain. Rising generic competition and regulatory uncertainties for Keytruda post-2028 could pressure margins. The company’s cost-cutting initiatives, , aim to offset potential revenue gaps. Investors remain cautious as Merck balances growth in oncology and animal health with near-term headwinds in vaccines and diabetes therapies.

Backtesting a strategy involving an equal-weighted basket of the top 500 U.S. stocks by daily trading volume is currently constrained by platform limitations. The system requires a dedicated portfolio engine to dynamically rebalance and track such a strategy, which is not available in standard single-ticker backtesting tools. Alternative approaches, such as using a liquidity proxy index or analyzing single-ticker high-volume events, may approximate the concept but lack precision in capturing the full 500-stock dynamic.